Objectives: To identify patients who benefit from the salvage hormonal therapy in men with advanced prostate cancer who relapsed after primary hormonal therapy. Patients and Methods: The study included 68 patients treated with primary combined androgen blockade followed by second-line antiandrogen therapy at prostate-specific antigen (PSA) relapse. The cause-specific survival after second-line therapy was compared according to various clinical factors. Results: Of the several variables isolated as prognostic factors, the duration of response to first-line therapy remained as an independent prognostic factor by multivariate analysis. The comparative survival curves constructed according to the duration of response in first-line therapy and the responsiveness to second-line therapy clearly discriminate the patients' survival. The nadir PSA level in first-line therapy was well substituted for the responsiveness to second-line therapy, thereby enabling to predict the clinical outcome using the readily available variables before second-line therapy. Namely, the patients who failed to attain the duration of response ≥12 months and the nadir PSA <0.2 ng/ml in first-line therapy are unlikely to benefit from second-line therapy. Conclusions: These results may imply an inherent unresponsiveness to salvage hormonal therapy in patients who showed insufficient response to primary hormonal therapy and therefore an early introduction of chemotherapy might be an option for such patients.

Keywords:
Prostate cancer, Combined androgen blockade, Second-line hormonal therapy, Antiandrogen
1.
Crawford ED: Epidemiology of prostate cancer. Urology 2003;62(suppl 1):3-12.
2.
Cancer Registration Committee of the Japanese Urological Association: Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12:46-61.
3.
Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H, Japan Study Group of Prostate Cancer (J-CaP): Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 2007;37:775-781.
4.
Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-1498.
5.
Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997;15:2928-2938.
6.
Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO, Chatta GS, Lowe BA, Eisenberger MA, Crawford ED: Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001;58:53-58.
7.
Desai A, Stadler WM, Vogelzang NJ: Nilutamide: possible utility as a second-line hormonal agent. Urology 2001;58:1016-1020.
8.
Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H: Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171:679-683.
9.
Miyake H, Hara I, Eto H: Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005;96:791-795.
10.
Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y: Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol 2007;14:264-267.
11.
Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T, Kyoto Prefectural University of Medicine Prostate Cancer Research Group: Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 2007;14:128-132.
12.
Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group: Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921-927.
13.
Suzuki H, Ueda T, Ichikawa T, Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003;10:209-216.
14.
Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398.
15.
Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T: Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second-line therapy for advanced prostate cancer. J Urol 2000;164:1992-1995.
16.
Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS: Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175:27-34.
17.
Gleave ME, Small EJ: Androgen deprivation therapy for prostate cancer; in Carroll PR, Nelson WG (eds): Report to Nation Prostate Cancer. Elmwood Park, Medscape, 2004, pp 27-36.
18.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
19.
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-245.
20.
Novara G, Galfano A, Secco S, Ficarra V, Artibani W: Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol Int 2009;82:249-255.
21.
Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (INT-0162): Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-3990.
22.
Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M: Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int 2005;96:503-507.
23.
Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-989.
24.
Nayyar R, Sharma N, Gupta NP: Prognostic factors affecting progression and survival in metastatic prostate cancer. Urol Int 2010;84:159-163.
25.
Normand G, Celhay O, Briffaux R, Pirès C, Doré B, Fromont G, Irani J: Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significance. Urol Int 2009;83:160-165.
26.
European Association of Urology. Guidelines on Prostate Cancer. Available at www.uroweb.org/guidelines/online-guidelines/.
27.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. Available at www.nccn.org/professionals/physician_gls/f_guidelines.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.